Intravitreal bevacizumab injection with grid laser photocoagulation for macular oedema in branch retinal vein occlusion

Abstract

AbstractPurpose To evaluate the effects of intravitreal bevacizumab (IVB) with grid laser photocoagulation for macular edema in branch retinal vein occlusion (BRVO).Methods This was a retrospective case series. Ten eyes in 10 patients with macular edema secondary to BRVO with at least 3 months of symptom duration were included. The mean follow‐up term was 70.2 ± 8.4 weeks. Patients underwent IVB at baseline and macular grid laser photocoagulation 1 week later. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were examined during the monthly follow‐up. If persistent or recurrent fluid collection appeared in optical coherence tomography (OCT) , additional IVB were performed. To evaluate differences between baseline and post‐treatment BCVA and CMT, Fisher exact test was performed.Results The mean baseline BCVA was 0.31±0.17 (mean±SD), and the mean CMT was 530±109 µm. The mean BCVA at 4, 12 and 24 weeks were 0.49±0.21 (p=0.030), 0.47±0.60 (p=0.038), and 0.41±0.85 (p=0.041), respectively. The mean CMT were 285±75 µm (p<0.01), 304±120 µm (p<0.01), and 325±145 µm (p=0.015). A mean 1.85 injections were administered and the second injection was done at a mean 3.52 months after baseline.Conclusion IVB and additional grid photocoagulation were effective for macular edema in BRVO, and the improvement maintained for 6 months.